iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics
10 Ottobre 2023 - 2:00PM
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven
innovator of precision antibody immunotherapies, announced today
that Matt Greving Ph.D., its Vice President of Platform
Technologies and Machine Learning, has been selected to present on
the Company's technology for enhancing bispecific T-cell engagers
(“TCE”) at the Festival of Biologics from Oct. 10-12 in Basel,
Switzerland.
The Festival of Biologics is one of the
industry's most prominent conferences focused on biologics and the
discovery and development of antibody-based therapeutics, bringing
together leaders from pharma, biotech, and academic and research
institutions.
Dr. Greving's presentation, titled "Enhancing
Bispecific T Cell Engager Discovery, Potency, Safety and
Developability with Machine Learning and Mammalian Display," will
provide an overview of how iBio's technology stack - including
epitope engineering, fully human antibody library and EngageTx™ for
bispecific optimization - potentially overcomes challenges in the
discovery of bispecific TCEs, a promising area of research in
immunotherapies for cancer. He will present data demonstrating how
iBio's machine learning (ML)-driven epitope steering and
mammalian-display antibody libraries efficiently discover diverse
TCE arms tuned for potency, toxicity, developability and cyno
cross-reactivity. The presentation will take place on Oct. 12 at
12:20 p.m. CET.
"Bispecific antibodies play a growing role in
cancer immunotherapy research because of their ability to guide
human immune cells to attack and destroy tumor cells with a single
molecule, but developing them is challenging," Dr. Greving said.
"We've demonstrated our technology can efficiently optimize
next-gen CD3-T cell engager bispecifics, and we believe we are well
positioned to use our platform to tackle hard-to-drug targets both
internally and with partners and collaborators."
Along with the presentation, Dr. Greving will
chair a session on AI and Machine Learning, titled "Pitfalls to
Avoid When Building an AI-Driven Platform Company," on Tuesday,
Oct. 10 at 2:20 p.m. CET.
About iBio, Inc.
iBio develops next-generation biopharmaceuticals
using computational biology and 3D-modeling of subdominant and
conformational epitopes, prospectively enabling the discovery of
new antibody treatments for hard-to-target cancers and other
diseases. iBio’s mission is to decrease drug failures, shorten drug
development timelines, and open up new frontiers against the most
promising targets. For more information,
visit www.ibioinc.com.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release
constitute "forward-looking statements" within the meaning of the
federal securities laws. Words such as "may," "might," "will,"
"should," "believe," "expect," "anticipate," "estimate,"
"continue," "predict," "forecast," "project," "plan," "intend" or
similar expressions, or statements regarding intent, belief, or
current expectations, are forward-looking statements. These
forward-looking statements are based upon current estimates and
assumptions and include statements regarding the Company’s patented
AI-powered tech stack or EngageTx offering an accelerated solution
to generating bispecific antibodies, the Company’s technology
overcoming challenges in the discovery of bispecific T-cell
engagers, the Company’s machine learning epitope steering and
mammalian-display antibody library efficiently discovering diverse
T-cell engager arms turned for potency, toxicity, developability,
and cyno cross-reactivity, and our technology having the ability
can optimize next-gen CD3-T cell engager bispecifics. While the
Company believes these forward-looking statements are reasonable,
undue reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are subject
to various risks and uncertainties, many of which are difficult to
predict that could cause actual results to differ materially from
current expectations and assumptions from those set forth or
implied by any forward-looking statements. Important factors that
could cause actual results to differ materially from current
expectations include, among others, the Company’s ability to
continue to execute its growth strategy; its ability to obtain
regulatory approvals for commercialization of its product
candidates, or to comply with ongoing regulatory requirements;
regulatory limitations relating to its ability to promote or
commercialize its product candidates for specific indications;
acceptance of its product candidates in the marketplace and the
successful development, marketing or sale of products; competition;
the Company’s ability to retain its key employees or maintain its
NYSE American listing; and the other factors discussed in the
Company’s filings with the SEC including the Company’s Annual
Report on Form 10-K for the year ended June 30, 2023, and the
Company’s subsequent filings with the SEC on Forms 10-Q and 8-K.
The information in this release is provided only as of the date of
this release, and the Company undertakes no obligation to update
any forward-looking statements contained in this release on account
of new information, future events, or otherwise, except as required
by law.
Contacts:
Stephen KilmeriBio, Inc.Investor Relations(646)
274-3580skilmer@ibioinc.com
Susan ThomasiBio, Inc.Media Relations(619)
540-9195Susan.thomas@ibioinc.com
Grafico Azioni iBio (AMEX:IBIO)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni iBio (AMEX:IBIO)
Storico
Da Mag 2023 a Mag 2024